New Moxiked

   
Product NEW MOXIKED EYE DROP
Composition
  • Moxifloxacin 0.5 % w/v
  • Ketorolac 0.5% w/v
  • HPMC 0.25%w/v
  • Benzalkonium chloride solution 0.02%v/v
Availability

5 ML FFS vial packing

Therapeutic Group Fourth generation fluroquinolone antibiotic + Non- steroidal anti-inflammatory drug(NSAID)
Mode of Action

Moxifloxacin:Inhibit enzyme DNA – gyrase and Topoisomerase IV thus inhibit bacterial DNA relication leading to death of bacteria

Ketorolac:Ketorolac inhibits the enzyme cyclooxygenase (COX),which is required for the synthesis of prostaglandins.

When COX is inhibited prostaglandins are not synthesized and therefore ketorolac inhibits inflammation.

Clinical Benefits

Maximum coverage of Ocular pathogens.

Controls Post – operative pain and inflammation.

Safe & effective choice after cataract surgery. .

Adverse Effects

Transient ocular burning or discomfort.

 

Yash Pharma Laboratories Pvt. Ltd. All Rights Reserved